Coded Aperture and Compton Imaging for the Development of $^{225}$Ac-based Radiopharmaceuticals

Abstract: Targeted alpha-particle therapy (TAT) has great promise as a cancer treatment. Arguably the most promising TAT radionuclide that has been proposed is $^{225}$Ac. The development of $^{225}$Ac-based radiopharmaceuticals has been hampered due to the lack of effective means to study the daughter redistribution of these agents in small animals at the preclinical stage. The ability to directly image the daughters, namely $^{221}$Fr and $^{213}$Bi, via their gamma-ray emissions would be a boon for preclinical studies. That said, conventional medical imaging modalities, including single photon emission computed tomography (SPECT) based on pinhole collimation, cannot be employed due to sensitivity limitations. As an alternative, we propose the use of both coded aperture and Compton imaging with the former modality suited to the 218-keV gamma-ray emission of $^{221}$Fr and the latter suited to the 440-keV gamma-ray emission of $^{213}$Bi. This work includes coded aperture images of $^{221}$Fr and Compton images of $^{213}$Bi in tumor-bearing mice injected with $^{225}$Ac-based radiopharmaceuticals. These results are the first demonstration of visualizing and quantifying the $^{225}$Ac daughters in small animals via coded aperture and Compton imaging and serve as a stepping stone for future radiopharmaceutical studies.